Crinetics Posts $6.2M Q4 Revenue with 125 Prescribers and $1.4B Cash
Crinetics generated $6.2M in Q4 revenue—$5.4M from PALSONIFY—with over 125 unique prescribers and 200+ enrollment forms driving early commercial traction. The company holds $1.4B cash after a January equity raise, funding operations through 2030, and will initiate a global seamless phase II/III trial of atumelnant in H1.
1. Q4 Financial Performance
Crinetics reported Q4 revenue of $6.2M, including $5.4M from its first commercial product, PALSONIFY. The company used $326.2M cash in 2025 and after a January equity offering holds approximately $1.4B, projecting operations funded through 2030, with 2026 GAAP opex guidance of $600–650M (non-GAAP $480–520M).
2. PALSONIFY Early Commercial Launch
PALSONIFY has been prescribed by over 125 unique physicians across community practices and pituitary centers, generating more than 200 enrollment forms in Q4, including 22 open-label extension participants transitioning to commercial supply. Early formulary wins with top US payers include label-aligned prior authorizations and no step edits, while roughly half of new patients access therapy through the CrinetiCARE Quick Start program.
3. Atumelnant Phase II/III Trial Plan
Crinetics will initiate a global seamless phase II/III EQUILIBRIUM trial for atumelnant in ACTH-dependent Cushing’s syndrome in H1, evaluating 20–80mg once-daily doses and glucocorticoid replacement strategies. Atumelnant demonstrated rapid, large reductions in 24-hour urinary free cortisol in an NIH study and is positioned as the first ACTH receptor antagonist tested in humans.